AstraZeneca reported that a phase 3 trial of a three-drug combination for the treatment of chronic obstructive pulmonary disease met eight out of its main objectives.
The KRONOS Phase III trial evaluated the efficacy and safety of triple combination therapy PT010 (budesonide/ glycopyrronium/formoterol fumarate) versus dual combination therapies Bevespi Aerosphere (glycopyrronium/formoterol fumarate), Symbicort Turbuhaler (budesonide/formoterol fumarate) and PT009 (budesonide/formoterol fumarate) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
The three-drug cocktail showed a significant reduction of exacerbations in patients with the disease compared with rival therapy. AstraZeneca said it plans on making a first regulatory submission for the drug in the second half of the year.
Read the press release